EP2393940B1 - Generation of random double-strand breaks in dna using enzymes - Google Patents
Generation of random double-strand breaks in dna using enzymes Download PDFInfo
- Publication number
- EP2393940B1 EP2393940B1 EP10704044.6A EP10704044A EP2393940B1 EP 2393940 B1 EP2393940 B1 EP 2393940B1 EP 10704044 A EP10704044 A EP 10704044A EP 2393940 B1 EP2393940 B1 EP 2393940B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dna
- vvn
- nuclease
- mutant
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004190 Enzymes Human genes 0.000 title description 32
- 108090000790 Enzymes Proteins 0.000 title description 32
- 230000005782 double-strand break Effects 0.000 title description 2
- 108020004414 DNA Proteins 0.000 claims description 74
- 101710163270 Nuclease Proteins 0.000 claims description 58
- 239000012634 fragment Substances 0.000 claims description 47
- 102000053602 DNA Human genes 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 238000012163 sequencing technique Methods 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 230000007017 scission Effects 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 2
- 108010042407 Endonucleases Proteins 0.000 description 30
- 102000004533 Endonucleases Human genes 0.000 description 30
- 239000000203 mixture Substances 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000011534 incubation Methods 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000006062 fragmentation reaction Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 238000013467 fragmentation Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000607265 Vibrio vulnificus Species 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229920000856 Amylose Polymers 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 101710147059 Nicking endonuclease Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000588700 Dickeya chrysanthemi Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000011186 acute T cell leukemia Diseases 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
Definitions
- Breaking genomic DNA into smaller distinct sizes of fragments is an important step in many sequencing technologies.
- Current mechanical fragmentation methods such as sonication, adaptive-focused acoustics or nebulization, generate DNA fragments without base cleavage preferences. These methods, however, have the potential to damage DNA in places other than the phosphodiester bond, and have a lower efficiency of DNA recovery compared to enzymatic methods.
- enzymatic methods such as those that rely on restriction enzymes with specific recognition sequences produce fragments of a fixed specific size that may be large or small depending on the frequency of the occurrence of the recognition sequences.
- WO 2005/052124 describes modulation of enzyme activity by changing reciprocal stereo-geometric positions of two catalytic centers in an enzyme.
- WO 2005/121946 describes inferring function from shotgun sequencing data.
- EP 1564306 describes methods for fragmenting and labelling DNA.
- a preparation in an embodiment of the invention, includes a non-specific nuclease and a T7 Endo I mutant in a unit ratio of less than 1:200.
- the non-specific nuclease is Vibrio vulnificus (Vvn) nuclease, which has a mutation at Q69.
- a method for generating fragments from large DNA suitable for sequencing that includes mixing a DNA of interest with a preparation, which contains a non-specific nuclease and a T7 Endo I mutant in a unit ratio of less than 1:200.
- the large DNA is cleaved into fragments of a size suitable for sequencing.
- an example of the non-specific nuclease for use in the method is Vvn nuclease more particularly a Vvn nuclease mutant with increased specific activity such as a mutation at Q69.
- Fragments of the large DNA may contain one or two blunt ends and can be further modified to ligate to adapters of the type used in sequencing DNA.
- compositions and methods are provided that rely on a mixture of enzymes in a preparation for producing double-stranded DNA fragments of approximately uniform size where the uniform size may be predetermined according to need and generated by, for example, varying the incubation time.
- the enzyme preparation reduces the number of non-productive nicks in dsDNA fragments compared with the dsDNA product of a non specific nuclease cleavage reaction alone by including a counter-nicking activity.
- the counter-nicking permits the creation of overhangs of defined length which will dissociate under normal dissociation conditions and which can be repaired to blunt ends for subsequent manipulation.
- Repair may involve chewing back a 3' overhang or synthesizing by means of a polymerase, a complementary sequence to a 5' overhang. Adaptors with blunt or single nucleotides overhang may then be ligated to the modified fragments. These fragments may then be used in various sequencing platforms.
- Random fragmentation methods in the prior art generate overhangs but these are not discretely sized and create at least two problems.
- dissociation of the ends is not uniform as melting temperatures depend on the length and base composition of the overhang.
- the preparation contains a non-specific nuclease and a T7endonuclease I or mutant thereof.
- a nuclease may be used which has a preference for cleaving AT or GC base pairs, preferably a nuclease is selected which does not have a significant bias for either GC or AT.
- An example of a nuclease belonging to this latter category is obtained from Vibrio vulnificus (Vvn) (GI: 2625684 Wu, et al. Appl Environ Microbiol 67(1): 82-8 (2001 ).
- extracellular nucleases that may be utilized in the preparation include Dns from Vibrio cholera ( Focareta and Manning Gene 53(1): 31-40 (1987 ); NucM from Erwinia chrysanthemi ( Moulard, et al. Mol Microbiol 8(4): 685-95 (1993 ); Endo I from E. coli ( Jekel, et al Gene 154(1): 55-59 (1995 ); Dns and DnsH from Aeromonas hydrophila ( Chang et al. Gene 122(1): 175-80 (1992 ) and Dodd, et al. FEMS Microbiol Lett 173(1): 41-6 (1999 ); Wang, et al. Nucleic Acids Res 35: 584-94 (2007 ); and Wang, et al. Nucleic Acid Res. 35: 584-594 (2007 )).
- mutations to the nuclease can result in improved specific activity.
- mutations of Q69 of the Vvn endonuclease results in a nuclease with enhanced specific activity.
- the examples utilize Q69S.
- Mutant nucleases were found to be readily produced in host cells when, for example, the gene was coupled with the gene for MBP to create a fusion protein that accumulates in the periplasmic space for improved recovery of the mutant endonuclease.
- T7 Endo I mutant to an enzyme preparation containing a non-specific nuclease had an important beneficial effect on the generation of fragments with desired properties.
- Nicks created by non-specific nucleases that produce fragments of different sizes under denaturing conditions effectively disappeared in the presence of a T7 Endo I mutant because of its counter-nicking activity.
- the counter-nicking activity generated fragments with ends that could readily dissociate preferably 8 nucleotides or less from the nick site.
- Other beneficial effects of the enzyme mixture on dsDNA included production of DNA fragments which had a predictable overhang disposition and length that were suitable for repair or removal to permit attachment of adaptors that is sometimes required for DNA sequencing platforms.
- a plurality of nucleases are combined in a reaction mixture where at least one nuclease is of the type capable of introducing random nicks throughout the DNA on either strand and a second nuclease is capable of counter-nicking in the immediate vicinity of this first nick, but in the opposite strand of the DNA duplex, thus causing a double-stranded DNA break.
- Plasmid DNA and different types of genomic DNA were enzymatically cleaved into DNA fragments of a size suitable for sequencing methodologies using an enzyme preparation as described above. Following the fragmentation of the DNA, DNA fragments were gel-isolated and processed for next generation sequencing.
- the assay provided in Example 2 may be used to identify the appropriate amount of nucleases for a selected time of incubation for any particular DNA or an appropriate time of incubation for a selected ratio of nucleases.
- the unit ratio of the two nucleases is less than 1:200, for example less than 1:100, for example, less than 1:10.
- the range may be 1:2 to 1:200.
- T7 Endo I or mutant thereof was defined as the amount of enzyme required to convert 90% of 2 ⁇ g of the linear-nicked 2.44 kb dsDNA into two fragments (1.37 kb and 1.07 kb) at 37°C for 1 hour.
- Vvn nuclease and mutants thereof is defined as the amount of enzyme required to release 1 A 260 unit of acid soluble oligonucleotides in 30 min at 37°C.
- the optimal time of incubation for the DNA fragmentation reaction may be assayed according to whether the DNA falls in the range of greater than 60% GC (high GC content), 40%-60% GC (standard GC content), or less than 40% GC (low GC content).
- the incubation time range may be typically in the range of 10 minutes to 120 minutes, for example, 15 minutes to 60 minutes.
- “Large” constitutes a DNA having a size which requires fragmentation for sequencing.
- T7 Endo I mutant refers to a T7 Endo I with a mutation in the bridge region between the two catalytic domains.
- MBP-T7 Endo I mutant acts the same as T7 Endo I.
- MBP-Vvn nuclease acts the same as Vvn nuclease (WT or mutant).
- Non-specific nuclease refers to any DNA nuclease that does not recognize a specific DNA sequence.
- a DNA sequence consists of at least 2 nucleotides in a defined order. This excludes restriction endonucleases that recognize specific DNA sequences.
- Example 1 Preparation of an enzyme mixture containing Vvn or mutant thereof
- Vvn gene absent its signal peptide, corresponds to amino acids 19 through 231 in Figure 5 (SEQ ID NO:5). It was synthesized by PCR amplification using a pair of primers 1 (5'-AAGGTT GAATTC GCGCCACCTAGCTCCTTCTCT GCC-3') (SEQ ID NO:1) and 2 (5'-GGTAGA GGATCC TTATTGAGTTTGACAG GATTGCTG-3') (SEQ ID NO:2) and the fragment was cloned between the EcoRI and BamHI of pMALp4x vector (NEB, Ipswich, MA, #N8104).
- the fusion protein MBP-Vvn endonuclease was expressed in the periplasmic compartment of E. coli and purified by an amylose affinity column to homogeneity.
- the MBP-Vvn nuclease (WT) was further purified by a Heparin column (GE Healthcare, Piscataway, NJ). Protein concentration was determined by a Bradford assay (Bio-Rad Laboratories, Inc., Hercules, CA).
- a mutant MBP-Vvn endonuclease (Q69S) was created, which had 5-10 fold greater specific activity than MBP-Vvn endonuclease (WT) ( Figures 3A - 3B ).
- primers 3 (5'-C AAGTACGCAAAAGCCAAACTCGCGCAT CG-3') (SEQ ID NO:3) and 2 (SEQ ID NO:2) were used to amplify the C-terminal part of the Vvn gene
- primers 1 (SEQ ID NO:1) and 4 (5'-TGCGCGAGTTTGGCTTTTGCGTA CTTGGTA-3') (SEQ ID NO:4) were used to amplify the N-terminal region of the Vvn gene, excluding the signal peptide sequence.
- Vvn mutant endonuclease (Q69S) amino acid sequence Is shown in Figure 5 .
- the fusion protein MBP-Vvn endonuclease (Q69S) was expressed in the periplasm of E. coli and purified by an amylose affinity column to homogeneity.
- pNB1 In order to prepare linear dsDNA with a specific nicked site, pNB1 was utilized (2.44Kb). pNB1 is a plasmid with single sites for cleavage by Nt.BstNBI and BsaI. Cleavage with BsaI linearizes the plasmid, while Nt.BstNBI introduces a site-specific nick at its recognition site.
- the plasmid pNB1 was digested with Nt.BstNBI and BsaI restriction enzyme at 50°C for one hour. Calf intestinal alkaline phosphatase was then added to the linear-nicked dsDNA and incubated at 37°C for one hour. This treatment prevented sealing of the Nt.BstNBI nick by E. coli ligase during the subsequent assay. Fragmented dsDNA was separated from associated enzymes using Qiagen columns (Valencia, CA).
- T7 Endo I mutant Treatment of the fragmented pNBI DNA with the T7 Endo I mutant introduced a counter-nick into the DNA strand approximately opposite the Nt.BstNBI nick to produce two fragments (1.37 kb and 1.07 kb) (see Figure 7 ).
- One unit of T7 Endo I mutant was defined as the amount of enzyme required to convert 90% of 2 ⁇ g of the linear-nicked 2.44 kb dsDNA into two fragments (1.37 kb and 1.07 kb) at 37°C for 1 hour with buffer containing 5 units of E.
- Lane 5 of Figure 7 shows a reaction that satisfies this definition.
- Vvn endonuclease mutant was added to 3 ml of a reaction mixture at 37°C containing 20 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 0.15% Triton X-100, 50 mM NaCl, sonicated calf thymus gDNA (3 mg) and BSA (0.1 mg/ml), and incubation continued at 37°C.
- 500 ⁇ l of reaction mixture was removed and the endonuclease activity was stopped with 500 ⁇ l of 5% TCA after 10, 20, 30, 40 and 50 minute time intervals.
- Vvn endonuclease mutant is defined as the amount of enzyme required to release 1 A 260 unit of acid soluble oligonucleotides in 30 min at 37°C.
- Vvn nuclease and T7 Endo I mutant were combined in a storage buffer of 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 0.1 mM EDTA, 200 ⁇ g/ml BSA and 50% glycerol at various ratios.
- DNA fragmentation buffer contained 20 mM Tris-HCl (pH7.5), 50 mM NaCl, 10. mM MgCl 2 , 0.15% Triton X-100 and 0.1 mg/ml BSA.
- one endonuclease was maintained in a constant amount while the other nuclease was varied in concentration under otherwise similar reaction conditions using a TCA assay.
- the unit ratio was approximately 3:1 for MBP-T7 Endo I mutant: MBP-Vvn endonucleases (Q69S) mutant.
- the unit ratio was decreased to 2:1, the rate of DNA degradation reduced 50% as determined by the TCA assay described above.
- the ratio was increased to 8:1, the rate only increased 14%.
- CB4 was shown to fragment genomic DNA from different sources and of different sizes in a time-dependent manner ( Figure 2 ).
- CB4 is a mixture of 2 volumes of MBP-T7 Endo I mutant (PA/A) (0.26 mg/ml) and 1 volume of MBP-Vvn (WT) (0.2 mg/ml)).
- PA/A MBP-T7 Endo I mutant
- WT MBP-Vvn
- CB4 also converted mixtures of small fragments with a size of 100-1500 bps into fragments of 100 to 150 bp ( Figure 2 ), a size suited to several current next generation sequencing platforms.
- FIGS 6A and 6B show how treatment of plasmids with either MBP-Vvn nuclease (Q69S) or MBP-T7 Endo I PA/A over increasing times of incubation resulted in increased accumulation of nicked circular DNA, followed by formation of linear plasmid and degradation of this DNA into smaller fragments.
- the desired degradation of any particular DNA is a function of the size of the starting DNA, the size of the desired fragments and the time of incubation with a selected ratio of nucleases in the mixture.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14967509P | 2009-02-03 | 2009-02-03 | |
US15881509P | 2009-03-09 | 2009-03-09 | |
US27553109P | 2009-08-31 | 2009-08-31 | |
PCT/US2010/023007 WO2010091060A1 (en) | 2009-02-03 | 2010-02-03 | Generation of random double strand breaks in dna using enzymes |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2393940A1 EP2393940A1 (en) | 2011-12-14 |
EP2393940B1 true EP2393940B1 (en) | 2014-12-17 |
Family
ID=42102827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10704044.6A Active EP2393940B1 (en) | 2009-02-03 | 2010-02-03 | Generation of random double-strand breaks in dna using enzymes |
Country Status (4)
Country | Link |
---|---|
US (1) | US8703462B2 (zh) |
EP (1) | EP2393940B1 (zh) |
CN (1) | CN102301009B (zh) |
WO (1) | WO2010091060A1 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014150938A1 (en) * | 2013-03-15 | 2014-09-25 | Dana-Farber Cancer Institute, Inc. | Methods for generating nucleic acid molecule fragments having a customized size distribution |
WO2015089243A1 (en) | 2013-12-11 | 2015-06-18 | The Regents For Of The University Of California | Methods for labeling dna fragments to recontruct physical linkage and phase |
CN104195122B (zh) * | 2014-05-26 | 2017-01-04 | 杭州师范大学 | Yep非特异性核酸酶、基因、载体、工程菌及应用 |
EP3919621A1 (en) * | 2014-06-23 | 2021-12-08 | The General Hospital Corporation | Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq) |
CA2956925C (en) | 2014-08-01 | 2024-02-13 | Dovetail Genomics, Llc | Tagging nucleic acids for sequence assembly |
CA2976902A1 (en) | 2015-02-17 | 2016-08-25 | Dovetail Genomics Llc | Nucleic acid sequence assembly |
GB2554572B (en) | 2015-03-26 | 2021-06-23 | Dovetail Genomics Llc | Physical linkage preservation in DNA storage |
KR20180096586A (ko) | 2015-10-19 | 2018-08-29 | 더브테일 제노믹스 엘엘씨 | 게놈 어셈블리, 하플로타입 페이징 및 표적 독립적 핵산 검출을 위한 방법 |
WO2017100343A1 (en) * | 2015-12-07 | 2017-06-15 | Arc Bio, Llc | Methods and compositions for the making and using of guide nucleic acids |
SG11201807117WA (en) | 2016-02-23 | 2018-09-27 | Dovetail Genomics Llc | Generation of phased read-sets for genome assembly and haplotype phasing |
US10160987B2 (en) | 2016-04-07 | 2018-12-25 | Rebecca F. McClure | Composition and method for processing DNA |
EP3954771A1 (en) | 2016-05-13 | 2022-02-16 | Dovetail Genomics, LLC | Recovering long-range linkage information from preserved samples |
DK3464628T5 (da) | 2016-06-06 | 2024-10-14 | Redvault Biosciences Lp | Target reporter constructs and uses thereof |
US20200017862A1 (en) * | 2017-03-07 | 2020-01-16 | University Of North Carolina Charlotte | Systems and methods for single-strand break signaling and repair in a cell-free system |
CN107217308A (zh) * | 2017-06-21 | 2017-09-29 | 北京贝瑞和康生物技术股份有限公司 | 一种用于检测染色体拷贝数变异的测序文库构建方法和试剂盒 |
CN111763664B (zh) * | 2020-06-28 | 2021-03-26 | 江苏康科斯医疗科技有限公司 | 一种用于构建测序文库的酶反应液及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1906292B (zh) * | 2003-11-21 | 2013-03-27 | 新英格兰生物实验室公司 | 修饰的dna切割酶和其应用方法 |
US7851192B2 (en) * | 2004-11-22 | 2010-12-14 | New England Biolabs, Inc. | Modified DNA cleavage enzymes and methods for use |
US20050191682A1 (en) * | 2004-02-17 | 2005-09-01 | Affymetrix, Inc. | Methods for fragmenting DNA |
EP1754141A4 (en) * | 2004-06-02 | 2008-01-02 | New England Biolabs Inc | INFERENCE FUNCTION FROM BLIND SEQUENCING DATA |
-
2010
- 2010-02-03 EP EP10704044.6A patent/EP2393940B1/en active Active
- 2010-02-03 US US13/140,901 patent/US8703462B2/en active Active
- 2010-02-03 WO PCT/US2010/023007 patent/WO2010091060A1/en active Application Filing
- 2010-02-03 CN CN201080005891.XA patent/CN102301009B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
WO2010091060A1 (en) | 2010-08-12 |
CN102301009B (zh) | 2015-09-30 |
US8703462B2 (en) | 2014-04-22 |
EP2393940A1 (en) | 2011-12-14 |
US20110256593A1 (en) | 2011-10-20 |
CN102301009A (zh) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2393940B1 (en) | Generation of random double-strand breaks in dna using enzymes | |
AU2022200686B2 (en) | Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using CRISPR/Cas system proteins | |
US20200087652A1 (en) | Capture of nucleic acids using a nucleic acid-guided nuclease-based system | |
JP6108494B2 (ja) | 1本鎖dnaの鋳型非依存性ライゲーション | |
CN105705515B (zh) | 多种用于dna操作的转座酶适体 | |
EP2545183B1 (en) | Production of single-stranded circular nucleic acid | |
EP4249602A2 (en) | Method of preparing libraries of template polynucleotides | |
CA3106822C (en) | Method for editing dna in cell-free system | |
McNeil et al. | Group II introns: versatile ribozymes and retroelements | |
US8795968B2 (en) | Method to produce DNA of defined length and sequence and DNA probes produced thereby | |
AU2018297861C1 (en) | DNA production method and DNA fragment joining kit | |
WO2018005720A1 (en) | Method of determining the molecular binding between libraries of molecules | |
US20210388414A1 (en) | Optimization of in vitro isolation of nucleic acids using site-specific nucleases | |
WO2005095605A1 (en) | Process for reducing the number of mismatches in double stranded polynucleotides | |
US20240271328A1 (en) | Rapid library construction for high throughput sequencing | |
US20220186212A1 (en) | Method for constructing library on basis of rna samples, and use thereof | |
CN115461457A (zh) | 双链核酸分子及利用其去除dna文库中glass接头的方法 | |
JP5780971B2 (ja) | 酵素を使用するdnaにおけるランダム二本鎖切断 | |
US11261483B2 (en) | Programmable DNA-guided artificial restriction enzymes | |
US10894979B2 (en) | Construction of next generation sequencing (NGS) libraries using competitive strand displacement | |
JP2023540177A (ja) | ヘアピンアダプターを使用して配列決定ライブラリーから標的配列を濃縮する方法 | |
JPWO2021232023A5 (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110805 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20140127 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20140801 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 701980 Country of ref document: AT Kind code of ref document: T Effective date: 20150115 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010021023 Country of ref document: DE Effective date: 20150129 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150317 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150318 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 701980 Country of ref document: AT Kind code of ref document: T Effective date: 20141217 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150417 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010021023 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150203 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150228 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150228 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
26N | No opposition filed |
Effective date: 20150918 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150203 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20100203 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150417 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141217 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602010021023 Country of ref document: DE Representative=s name: ZACCO LEGAL RECHTSANWALTSGESELLSCHAFT MBH, DE |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230515 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231227 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20231227 Year of fee payment: 15 Ref country code: FR Payment date: 20231227 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240124 Year of fee payment: 15 |